Phenotype-based probabilistic analysis of heterogeneous responses to cancer drugs and their combination efficacy

Quantifying Drug Combination Synergy along Potency and Efficacy Axes

(2019) Christian T. Meyer et al.   Cell Systems

MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas

(2019) Ophélia Maertens et al.   Cancer Discovery

HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy

(2019) Michael F. Emmons et al.   CANCER RESEARCH

Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency

(2019) Khaliq et al.   Cancers

Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma

(2018) Yong Yu et al.   CANCER CELL

Toward Minimal Residual Disease-Directed Therapy in Melanoma

(2018) Florian Rambow et al.   CELL

An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential

(2018) Liqin Wang et al.   CELL

Co‐targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor‐resistant melanoma

(2018) Ileabett M Echevarría‐Vargas et al.   EMBO Molecular Medicine

Fluctuations in p53 Signaling Allow Escape from Cell-Cycle Arrest

(2018) José Reyes et al.   MOLECULAR CELL

Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state

(2017) Mohammad Fallahi‐Sichani et al.   Molecular Systems Biology

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

(2017) Sydney M. Shaffer et al.   NATURE

Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition

(2017) Matthew J. Hangauer et al.   NATURE

An Introduction to Terminology and Methodology of Chemical Synergy—Perspectives from Across Disciplines

(2017) Kyle R. Roell et al.   Frontiers in Pharmacology

Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC)

(2017) J. A. Sosman et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of phenotypic plasticity in the escape of cancer cells from targeted therapy

(2016) Michael F. Emmons et al.   BIOCHEMICAL PHARMACOLOGY

The cellular origins of drug resistance in cancer

(2016) Geoffrey R Oxnard   NATURE MEDICINE

A framework for understanding and targeting residual disease in oncogene-driven solid cancers

(2016) Trever G Bivona et al.   NATURE MEDICINE

An unbiased metric of antiproliferative drug effect in vitro

(2016) Leonard A Harris et al.   NATURE METHODS

Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs

(2016) Marc Hafner et al.   NATURE METHODS

Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

(2016) Michael Ramirez et al.   Nature Communications

Systematic analysis of BRAFV600E melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis

(2015) M. Fallahi-Sichani et al.   Molecular Systems Biology

Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model

(2015) Bhagwan Yadav et al.   Computational and Structural Biotechnology Journal

Patient-derived models of acquired resistance can identify effective drug combinations for cancer

(2014) Adam S. Crystal et al.   SCIENCE

Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells

(2013) Alexander Roesch et al.   CANCER CELL

Rethinking cellular drug response

(2013) Jeremy L Jenkins   Nature Chemical Biology

Metrics other than potency reveal systematic variation in responses to cancer drugs

(2013) Mohammad Fallahi-Sichani et al.   Nature Chemical Biology

Understanding synergy

(2012) Nori Geary   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency

(2012) Guo Wei et al.   CANCER CELL

Fractional proliferation: a method to deconvolve cell population dynamics from single-cell data

(2012) Darren R Tyson et al.   NATURE METHODS

Fiji: an open-source platform for biological-image analysis

(2012) Johannes Schindelin et al.   NATURE METHODS

Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma

(2011) J de Lange et al.   ONCOGENE

A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations

(2010) Sreenath V. Sharma et al.   CELL

Dissecting Variability in Responses to Cancer Chemotherapy Through Systems Pharmacology

(2010) R Yang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning

(2009) Thouis R. Jones et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer Cells Display Profound Intra- and Interline Variation following Prolonged Exposure to Antimitotic Drugs

(2008) Karen E. Gascoigne et al.   CANCER CELL

Visualizing Spatiotemporal Dynamics of Multicellular Cell-Cycle Progression

(2008) Asako Sakaue-Sawano et al.   CELL

Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

(2008) Nilofer S. Azad et al.   JOURNAL OF CLINICAL ONCOLOGY

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

(2008) K. S.M. Smalley et al.   MOLECULAR CANCER THERAPEUTICS

Dynamic Proteomics of Individual Cancer Cells in Response to a Drug

(2008) A. A. Cohen et al.   SCIENCE

Modeling a Snap-Action, Variable-Delay Switch Controlling Extrinsic Cell Death

(2008) John G Albeck et al.   PLOS BIOLOGY